AWM Investment Company Inc. Reduces Stake in Repligen Co. (NASDAQ:RGEN)

AWM Investment Company Inc. cut its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,000 shares of the biotechnology company's stock after selling 5,000 shares during the period. AWM Investment Company Inc. owned about 0.12% of Repligen worth $9,356,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Signaturefd LLC lifted its stake in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new position in shares of Repligen during the 4th quarter valued at $29,000. Raiffeisen Bank International AG purchased a new stake in Repligen during the fourth quarter valued at about $29,000. Itau Unibanco Holding S.A. bought a new position in Repligen during the fourth quarter worth about $40,000. Finally, UMB Bank n.a. increased its stake in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

RGEN has been the subject of several analyst reports. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a report on Tuesday, April 29th. Royal Bank of Canada reduced their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Stock Down 1.9%

NASDAQ:RGEN traded down $2.30 during mid-day trading on Monday, hitting $118.15. 615,767 shares of the company's stock were exchanged, compared to its average volume of 740,875. The business has a fifty day moving average price of $130.28 and a 200 day moving average price of $144.49. The company has a market cap of $6.64 billion, a PE ratio of -231.67, a P/E/G ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a one year low of $102.97 and a one year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.28 earnings per share. Equities analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.